ANNX - NASDAQ
Annexon, Inc.
$5.39
+2.5%Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
At a Glance
Live SnapshotAnnexon, Inc. Management Team
Mr. Douglas E. Love Esq., J.D.
Chief Executive Officer, President & Director
Compensation
$1,010,807
Dr. Dean R. Artis Ph.D.
Chief Scientific Officer & Executive Vice President
Compensation
$797,380
Mr. Michael Overdorf M.B.A.
Executive Vice President & Chief Business Officer
Compensation
$580,469
Dr. Jamie Dananberg M.D.
Executive Vice President & Chief Medical Officer
Compensation
$715,233
Ms. Jennifer Lew CPA
Executive Vice President, Chief Financial Officer & Corporate Secretary
Compensation
$624,195
Dr. Ted Yednock Ph.D.
Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board
Compensation
$714,668
Mr. Shikhar Agarwal M.B.A.
Senior Vice President & Head of Commercial
Dr. Sunil Mehta Pharm.D.
Senior Vice President of Medical Affairs
Mr. Henk-Andre Kroon M.D.
Senior Vice President of Translational Medicine
Annexon, Inc. Insider Positioning
During the last 12 months, insiders have purchased $13.33M and sold $321K worth of ANNX shares, resulting in $13.01M of net buying activity.
3 Months
637.5K
3.46M
0
0.00
+3.5M
+$3.46M
3-6 Months
4.1K
20.66K
59.7K
313.42K
-293K
-$293K
6-9 Months
2.4M
8.84M
0
0.00
+8.8M
+$8.84M
9-12 Months
397.3K
1.01M
3.1K
7.99K
+1.0M
+$1.00M
Top Buyers
Satter Muneer A
Director
$12.12M
Carson William H.
Director
$375K
Choi Jung
Director
$279K
Waddill William D.
Director
$140K
Jones William A Jr
Director
$140K
Top Sellers
Yednock Ted
Officer: Evp & Chief Innovation Officer
$73K
Lew Jennifer
Officer: Evp & Chief Financial Officer
$73K
Artis Dean Richard
Officer: Evp & Chief Scientific Officer
$59K
Dananberg Jamie
Officer: Chief Medical Officer
$59K
Overdorf Michael
Officer: Evp & Chief Business Officer
$57K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $13.01M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
ANNX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 09, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 22, 2021 | June 02, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.